Patents Examined by Tracy Vivlemore
  • Patent number: 10093926
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: October 9, 2018
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Patent number: 10081060
    Abstract: A method of reducing silver(I) salts to silver nanoparticles employing a carbohydrate reductant in the presence of an inorganic base, a surfactant and optionally a polymer. The method is performed in an aqueous solution at a temperature up to 60° C. and for a duration of up to 40 minutes.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: September 25, 2018
    Assignee: King Abdulaziz University
    Inventors: Hassan Amroun Ewais, Iqbal Mohamed Ismail
  • Patent number: 10076536
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: September 18, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Ryszard Kole, Richard Keith Bestwick
  • Patent number: 10072097
    Abstract: The present invention discloses a novel isolated antibody that specifically binds to an N-phenyl-acetamide group. Also disclosed are related compositions, kits, methods for detecting protein S-nitrosylation or oxidation vivo or in vitro, and drug screening methods.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: September 11, 2018
    Assignee: Academia Sinica
    Inventors: Tzu-Ching Meng, Geen-Dong Chang, Ming-Fo Hsu
  • Patent number: 10071029
    Abstract: A cosmetic composition is disclosed comprising particle active; opacifying particles having a refractive index of at least 1.7 and cosmetically acceptable carrier. The particle active comprises (i) water-insoluble shell component comprising inorganic material and having a refractive index of from 1.3 to 1.8; and (ii) core component comprising volatile liquid and having a refractive index of at least 1.2.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: September 11, 2018
    Assignee: Conopco, Inc.
    Inventors: Florian Hudelist, Yajuan Li, Zhaoting Liu, Sheng Meng, Qiang Qiu, Lin Wang, Xiaoli Wang, Chunwei Wu
  • Patent number: 10064801
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs and lasiRNAs) that inhibit tyrosinase expression and are therefore useful for reducing melanin production and for treating pigmentation-related disorders associated with excessive melanin production, such as melasma and age spots.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 4, 2018
    Assignee: OliX Pharmaceuticals, Inc.
    Inventors: Sun Woo Hong, Isu Hong, Ji Hyun Kim
  • Patent number: 10067137
    Abstract: The present invention relates to a nanocomposition capable of capturing or enriching an analyte at a sub-nanogram level and methods thereof. The nanocomposition can comprise a nanostructure operably linked to an analyte-capturing member.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: September 4, 2018
    Assignee: NVIGEN, INC.
    Inventors: Aihua Fu, Zheng Meng
  • Patent number: 10059941
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: August 28, 2018
    Assignees: Translate Bio MA, Inc., The General Hospital Corporation
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 10058623
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of UTRN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of UTRN. Methods for modulating expression of UTRN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of UTRN.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: August 28, 2018
    Assignees: Translate Bio MA, Inc., The General Hospital Corporation
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 10060915
    Abstract: The present disclosure provides compositions and methods useful for molecular and cellular separation, detection and quantification. The compositions provided herein comprise a nanostructure having magnetic property operably linked to an analyte-binding member.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: August 28, 2018
    Assignee: NVIGEN, INC.
    Inventors: Aihua Fu, James Zhu
  • Patent number: 10052283
    Abstract: Disclosed is a composition for forming an injectable hydrogel. The composition includes 1% by weight or less of a graphene-based material and 5% by weight or more of a triblock copolymer. The triblock copolymer may be a copolymer represented by Formula 1: wherein n is an integer from 8 to 540, m is an integer from 16 to 70, and R is H or a vinylcarbonyl group (CH2?CHCO—). When R in Formula 1 is a vinylcarbonyl group, the triblock copolymer may be crosslinked through the vinylcarbonyl group to form a nanogel. The composition can be prepared by a simple mixing process. In addition, the composition is substantially free from in vitro and in vivo stability problems encountered with conventional hydrogel compositions. Furthermore, the composition has high biocompatibility as well as excellent mechanical properties such as high storage modulus.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: August 21, 2018
    Assignee: Gwangju Institute of Science and Technology
    Inventors: Giyoong Tae, Da-ae Won
  • Patent number: 10048264
    Abstract: The present invention relates to a lung cancer biomarker for diagnosing early stage lung cancers or predicting prognosis of lung cancers, which comprises a GM2AP protein. The present invention also relates to a method for diagnosing early stage lung cancers or predicting prognosis of lung cancers in vitro by detection of the biomarker.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: August 14, 2018
    Assignees: ACADEMIA SINICA, NATIONAL TAIWAN UNIVERSITY
    Inventors: Shui-Tein Chen, Chong-Jen Yu, Potprommanee Laddawan, Haou-Tzong Ma
  • Patent number: 10047386
    Abstract: Methods for detecting abdominal aortic aneurysm (AAA) or predisposition to AAA in a apoE subject, methods for monitoring the efficacy of treatment of AAA in a subject, and methods for evaluating the severity of AAA or risk of AAA in a subject involve measuring the amount of tetrahydrobiopterin (H4B) present in the test sample and comparing it to the amount of H4B present in a standard or previous test sample. A decreased amount of H4B present in the test sample compared to the standard is indicative of AAA or predisposition to AAA. Treatment can be administered to the subject prior to a second time point, and an increased amount of H4B present in the second test sample compared to the first test sample is indicative of effective treatment of AAA. Candidates can be identified for further testing or monitoring for AAA, and/or for treatment for AAA.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: August 14, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Hua Cai
  • Patent number: 10041070
    Abstract: The present invention discloses microRNAs (miR) involved in the regulation of the lipid and glucose metabolism. Several conserved miR molecules were found as direct targets of the glucocorticoid hormone/glucocorticoid receptor signaling axis. Hence, the present invention pertains to inhibitors of these miRs—such as antimiRs and blockmiRs—as well as isolated miR molecules or miR expression constructs for the treatment or prevention of metabolic disorders caused by deregulated glucocorticoid signaling, such as insulin resistance, the metabolic syndrome, obesity and/or diabetes type II. Particular preferred embodiments of the invention pertain to antagonists or agonists of a miR of the conserved miR-379-410 cluster, particularly of miR-379.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: August 7, 2018
    Assignees: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts, Ruprecht-Karls-Universität Heidelberg
    Inventors: Mauricio Berriel Diaz, Roldan De Guia, Stephan Herzig
  • Patent number: 10035736
    Abstract: A seed composition comprising a seed and a first component comprising an agriculturally acceptable complex mixture of dissolved organic material characterized by natural organic matter that is partially humified and methods of seed treating. A method comprising contacting a seed with a first component comprising an agriculturally acceptable complex mixture of dissolved organic material characterized by natural organic matter that is partially humified, where the first component enhances at least one of germination, emergence, root development, seedling vigor, seedling growth, mortality resistance, chlorophyll production, cold resistance, water log resistance, and nutrient uptake compared to similar seed not contacted with the first component.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: July 31, 2018
    Assignee: FBSCIENCES HOLDINGS, INC.
    Inventor: Brian B. Goodwin
  • Patent number: 10034478
    Abstract: Compositions having antimicrobial activity contain surface functionalized particles comprising an inorganic copper salt which has low water solubility. These types of inorganic salts may also be introduced in porous particles to yield antimicrobial compositions. The compositions may optionally comprise additional antimicrobial agents, salts with high water solubility, organic acids, salts of organic acids and their esters. The compositions may be added to various fluids used in the petroleum extraction industry, or used as coatings on components used in this industry. These antimicrobial materials may be used for reducing both anaerobic and aerobic bacteria and are also useful for reducing corrosion of ferrous components caused by anaerobic bacteria. Although such compositions may be used for any antimicrobial application, and some of the other important uses of these compositions are in wound care, personal care and waste processing.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: July 31, 2018
    Assignee: Agienic, Inc.
    Inventors: Nicholas R. Krasnow, Anoop Agrawal, Donald R. Uhlmann, John P. Cronin, Murat Akarsu, Ryan J. Reeser, Lori L. Adams
  • Patent number: 10031139
    Abstract: The present invention provides a staining method in which the fluorescent staining properties in a fluorescently-immunostained specimen are not reduced even when an oil-based mounting medium is used. The present invention also provides a method of preventing deterioration of a fluorescent label caused by irradiation with excitation light and improving the light resistance in a fluorescently-immunostained specimen obtained by the staining method. The biological substance detection method according to the present invention is a biological substance detection method for specifically detecting a biological substance from a pathological specimen, which includes the steps of: immunostaining the specimen with a fluorescent label; immobilizing the thus stained specimen; and mounting the thus immobilized specimen using a mounting medium including an organic solvent not freely miscible with water.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: July 24, 2018
    Assignee: KONICA MINOLTA, INC.
    Inventors: Kensaku Takanashi, Hideki Gouda, Keizou Takano, Hideki Hoshino, Yasushi Nakano, Kohsuke Gonda, Noriaki Ohuchi, Mika Watanabe
  • Patent number: 10023863
    Abstract: This invention provides single-stranded and multi-stranded compounds that are useful in various therapeutic modalities to regulate the expression of nucleic acid molecules in a cell. A range of compounds is provided, each containing one or more conformationally restricted nucleomonomers (CRN). In addition, compounds can contain one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (unlocked nucleomonomers, UNA).
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: July 17, 2018
    Assignee: Marina Biotech, Inc.
    Inventors: Michael V. Templin, Narendra K. Vaish, Kathy L. Fosnaugh, Shaguna Seth, Michael E. Houston, Jr.
  • Patent number: 10016525
    Abstract: Compositions having antimicrobial activity contain surface functionalized particles comprising an inorganic copper salt which has low water solubility. These types of inorganic salts may also be introduced in porous particles to yield antimicrobial compositions. The compositions may optionally comprise additional antimicrobial agents, salts with high water solubility, organic acids, salts of organic acids and their esters. The above compositions can be incorporated in a variety of wound care products to provide antimicrobial properties.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: July 10, 2018
    Assignee: Agienic, Inc.
    Inventors: Lori L. Adams, Nicholas R. Krasnow, Anoop Agrawai, Donald R. Uhlmann
  • Patent number: 10017766
    Abstract: The invention relates to si RNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the FLAP gene. The invention also relates to the use of said si RNAs molecules in the treatment and/or prevention of an eye condition characterized by increased expression and/or activity of FLAP gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: July 10, 2018
    Assignee: SYLENTIS SAU
    Inventors: Ana Isabel Jimenez, Covadonga Pañeda, Tamara Martinez